Literature DB >> 30546904

A novel prognostic prediction model for recurrence in patients with stage II colon cancer after curative resection.

Kazuhiro Saso1, Norikatsu Myoshi1,2, Shiki Fujino1, Yuya Takenaka2, Yusuke Takahashi2, Junichi Nishimura2, Masayoshi Yasui2, Masayuki Ohue2, Masayoshi Tokuoka3, Yoshito Ide3, Hidekazu Takahashi1, Naotsugu Haraguchi1, Taishi Hata1, Chu Matsuda1, Tsunekazu Mizushima1, Yuichiro Doki1, Masaki Mori1.   

Abstract

The present study aimed to clarify the risk factors for recurrence of stage II colon cancer in patients and to determine possible treatment options for postoperative adjuvant chemotherapy. A prediction model for recurrence in patients with stage II colon cancer after curative surgical resection was developed. The present study retrospectively investigated 436 patients who underwent curative resection for stage II colon cancer at Osaka International Cancer Institute and Yao Municipal Hospital between 2004 and 2012. Several clinicopathological factors were examined and the Cox regression model was used to develop a prediction model for recurrence. The prediction model was validated in an independent group of 213 patients who underwent surgery at Osaka University Hospital between 2001 and 2012. Univariate analysis revealed that preoperative serum carcinoembryonic antigen level, preoperative obstruction, tumor invasion, lymphatic invasion and venous invasion were significantly correlated with disease-free survival. Using these variables, a classification and regression tree was constructed as a prediction model. The prediction models were validated by external datasets in an independent patient group. The concordance indices for DFS after current surgical resection were 0.675 in the learning set and 0.552 in the validation set. To conclude, a novel, reliable and personalized prognostic model was developed to predict recurrence in patients with stage II colon cancer, which may help clinicians to determine and perform adjuvant chemotherapy.

Entities:  

Keywords:  CART; adjuvant chemotherapy; prediction model; recurrence; stage II colon cancer

Year:  2018        PMID: 30546904      PMCID: PMC6256127          DOI: 10.3892/mco.2018.1733

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  13 in total

1.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Labianca; B Nordlinger; G D Beretta; S Mosconi; M Mandalà; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

2.  NCCN Clinical Practice Guidelines in Oncology: colon cancer.

Authors:  Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett
Journal:  J Natl Compr Canc Netw       Date:  2009-09       Impact factor: 11.908

3.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2017-03       Impact factor: 11.908

4.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

5.  Adjuvant chemotherapy and prognostic factors in stage II colon cancer--Izmir Oncology Group Study.

Authors:  Yuksel Kucukzeybek; Ahmet Dirican; Lutfiye Demir; Serkan Yildirim; Murat Akyol; Yasar Yildiz; Ibrahim Vedat Bayoglu; Ahmet Alacacioglu; Umut Varol; Tarik Salman; Ibrahim Yildiz; Huseyin Can; Mustafa Oktay Tarhan
Journal:  Asian Pac J Cancer Prev       Date:  2015

6.  Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.

Authors:  Anthony C Wong; Shannon Stock; Deborah Schrag; Katherine L Kahn; Talya Salz; Mary E Charlton; Selwyn O Rogers; Karyn A Goodman; Nancy L Keating
Journal:  J Oncol Pract       Date:  2014-07-01       Impact factor: 3.840

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 8.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.

Authors:  Ulrike Leiter; Petra G Buettner; Thomas K Eigentler; Claus Garbe
Journal:  J Clin Oncol       Date:  2004-08-09       Impact factor: 44.544

10.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Kei Muro; Yoichi Ajioka; Yojiro Hashiguchi; Yoshinori Ito; Yutaka Saito; Tetsuya Hamaguchi; Hideyuki Ishida; Megumi Ishiguro; Soichiro Ishihara; Yukihide Kanemitsu; Hiroshi Kawano; Yusuke Kinugasa; Norihiro Kokudo; Keiko Murofushi; Takako Nakajima; Shiro Oka; Yoshiharu Sakai; Akihito Tsuji; Keisuke Uehara; Hideki Ueno; Kentaro Yamazaki; Masahiro Yoshida; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Michio Itabashi; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Yasuhiro Shimada; Keiichi Takahashi; Shinji Tanaka; Osamu Tsuruta; Toshiharu Yamaguchi; Naohiko Yamaguchi; Toshiaki Tanaka; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2017-03-27       Impact factor: 3.402

View more
  3 in total

1.  Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies.

Authors:  Wei Xu; Yazhou He; Yuming Wang; Xue Li; Jane Young; John P A Ioannidis; Malcolm G Dunlop; Evropi Theodoratou
Journal:  BMC Med       Date:  2020-06-26       Impact factor: 8.775

2.  A Prediction Model for Tumor Recurrence in Stage II-III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling.

Authors:  Po-Chuan Chen; Yu-Min Yeh; Bo-Wen Lin; Ren-Hao Chan; Pei-Fang Su; Yi-Chia Liu; Chung-Ta Lee; Shang-Hung Chen; Peng-Chan Lin
Journal:  Biomedicines       Date:  2022-02-01

3.  Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer.

Authors:  Ozgur Acikgoz; Burcin Cakan; Tarik Demir; Ahmet Bilici; Bala Basak Oven; Jamshid Hamdard; Oktay Olmuscelik; Omer Fatih Olmez; Mesut Seker; Ozcan Yildiz
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.